Cleared Traditional

K880315 - DADE ANTITHROMBIN III CHROMOGENIC ASSAY

K880315 is the FDA 510(k) clearance for DADE ANTITHROMBIN III CHROMOGENIC ASSAY by Baxter Healthcare Corp. It is a Class 2 Hematology device (product code JBQ) cleared through the Traditional 510(k) pathway after a 50-day FDA review.

K880315 · Baxter Healthcare Corp · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1988
Decision
50d
Days
Class 2
Risk

K880315 is an FDA 510(k) clearance for the DADE ANTITHROMBIN III CHROMOGENIC ASSAY. Classified as Antithrombin Iii Quantitation (product code JBQ), Class II - Special Controls.

Submitted by Baxter Healthcare Corp (Miami, US). The FDA issued a Cleared decision on March 16, 1988 after a review of 50 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7060 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Baxter Healthcare Corp devices

Submission Details

510(k) Number K880315 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 26, 1988
Decision Date March 16, 1988
Days to Decision 50 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
63d faster than avg
Panel avg: 113d · This submission: 50d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JBQ Antithrombin Iii Quantitation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7060
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - JBQ Antithrombin Iii Quantitation

All 39
Devices cleared under the same product code (JBQ) and FDA review panel - the closest regulatory comparables to K880315.
TURBOX ANTITHROMBIN III
K884144 · Unipath , Ltd. · Dec 1988
BERICHROM(R) ANTITHROMBIN III
K883662 · Behring Diagnostics, Inc. · Nov 1988
ENZYGNOST(R) TAT REAGENTS
K880700 · Behring Diagnostics, Inc. · Apr 1988
IL TEST 97574-15M, ANTITTHROMBIN III ASSASY
K864214 · Instrumentation Laboratory CO · Nov 1986
GEN. DIAG. CHROMOSTRATE ANTITHROMBIN III ASSAY
K850412 · Warner-Lambert Co. · May 1985
IL TEST ANTITHROMBIN III ACTIVITY
K841736 · Instrumentation Laboratory CO · Sep 1984